Track Regentis Biomaterials Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Regentis Biomaterials Ltd. RGNT · Stock Open Regentis Biomaterials Ltd. in new tab

7.13 USD
Add to portfolio
EPS
-24.16
P/B
7.78
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJune 30, 2026
EPS-24.16
Book Value0.92
Price to Book7.78
Debt/Equity25.23
% Insiders19.047%

DCF Valuation

Tweak assumptions to recompute fair value for Regentis Biomaterials Ltd. (RGNT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Regentis Biomaterials Ltd. Logo Regentis Biomaterials Ltd. Analysis (RGNT)

Israel Healthcare Official Website Stock

Is Regentis Biomaterials Ltd. a good investment? Regentis Biomaterials Ltd. (RGNT) is currently trading at 7.13 USD.

Earnings Schedule: Regentis Biomaterials Ltd. is expected to release its next earnings report on June 30, 2026.

Investor FAQ

Does Regentis Biomaterials Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Regentis Biomaterials Ltd.?

Regentis Biomaterials Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be June 30, 2026. The company currently has a trailing EPS of -24.16.

Company Profile

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Exchange Ticker
AMEX RGNT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion